PLATO
2009
Platelet Inhibition and Patient Outcomes
In 18,624 patients hospitalised with ACS, ticagrelor reduced CV death, MI or stroke compared with clopidogrel, with similar major bleeding.
Result
Efficacy: CV death, MI or stroke at 12 monthsHR 0.84
Below 1 favours ticagrelor, above 1 favours clopidogrel.
- Absolute difference
- 1.9 points
The absolute difference is derived from the event rates.
Also reported: All-cause mortality also reduced.
- Subtopic
- Antiplatelets
- Design
- Double-blind RCT, 12 mo
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ESC 2024 CCSESC 2023 ACSESC/EACTS 2018 RevascularisationACC/AHA 2025 ACSACC/AHA 2021 Revascularisation
- Source
- Wallentin L, et al. N Engl J Med. 2009;361(11):1045-1057.doi 10.1056/NEJMoa0904327
Discussion & critique
Regional heterogeneity (notably worse outcomes in the US sites) prompted FDA scrutiny: attributed to higher aspirin doses. Dyspnoea and bradycardia are notable adverse signals.